[go: up one dir, main page]

PE20110410A1 - Derivado de 7-piperidinoalquil-3,4-dihidroquinolona - Google Patents

Derivado de 7-piperidinoalquil-3,4-dihidroquinolona

Info

Publication number
PE20110410A1
PE20110410A1 PE2011000810A PE2011000810A PE20110410A1 PE 20110410 A1 PE20110410 A1 PE 20110410A1 PE 2011000810 A PE2011000810 A PE 2011000810A PE 2011000810 A PE2011000810 A PE 2011000810A PE 20110410 A1 PE20110410 A1 PE 20110410A1
Authority
PE
Peru
Prior art keywords
tetrahydroquinolin
benzamide
piperidin
oxo
alkylene
Prior art date
Application number
PE2011000810A
Other languages
English (en)
Inventor
Kosuke Kanuma
Naoki Miyakoshi
Madoka Kawamura
Tsuyoshi Shibata
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110410(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PE20110410A1 publication Critical patent/PE20110410A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 7-PIPERIDINOALQUIL-3,4-DIHIDROQUINOLONA DE FORMULA (I) DONDE R ES H O ALQUILO(C1-C6); A1, A2 Y A3 SON CADA UNO H, HALOGENO, ALQUILO(C1-C6) O ALCOXI(C1-C6); X ES ALQUILENO(C1-C6); Y ES UN ENLACE O ALQUILENO(C1-C6); Z ES UN ENLACE O ALQUILENO(C1-C6) OPCIONALMENTE SUSTITUIDO CON ARILO; W ES UN ENLACE U O; Cy ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS CON HALOGENO, CN, ALQUILO(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-METOXI-N-{1-[(2-OXO-1,2,3,4-TETRAHIDROQUINOLIN-7-IL)METIL]PIPERIDIN-4-IL}BENZAMIDA; 3-FLUORO-N-{1-[(2-OXO-1,2,3,4-TETRAHIDROQUINOLIN-7-IL)METIL]PIPERIDIN-4-IL}BENZAMIDA; 3,5-DIFLUORO-N-{1-[(2-OXO-1,2,3,4-TETRAHIDROQUINOLIN-7-IL)METIL]PIPERIDIN-4-IL}BENZAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE HORMONA PARA CONCENTRACION DE MELANINA (MCH) SIENDO UTILES EN EL TRATAMIENTO DE LA DEPRESION, DESORDENES DE ANSIEDAD, ESQUIZOFRENIA, AMNESIA, BULIMIA
PE2011000810A 2008-10-02 2009-09-30 Derivado de 7-piperidinoalquil-3,4-dihidroquinolona PE20110410A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008257072 2008-10-02

Publications (1)

Publication Number Publication Date
PE20110410A1 true PE20110410A1 (es) 2011-07-02

Family

ID=42073652

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000810A PE20110410A1 (es) 2008-10-02 2009-09-30 Derivado de 7-piperidinoalquil-3,4-dihidroquinolona

Country Status (28)

Country Link
US (1) US8461182B2 (es)
EP (1) EP2344471B1 (es)
JP (1) JP5541279B2 (es)
KR (1) KR20110067026A (es)
CN (1) CN102239159B (es)
AR (1) AR073727A1 (es)
AU (1) AU2009300607C1 (es)
BR (1) BRPI0925343A2 (es)
CA (1) CA2739513A1 (es)
CL (1) CL2011000734A1 (es)
CO (1) CO6321164A2 (es)
CY (1) CY1114165T1 (es)
DK (1) DK2344471T3 (es)
ES (1) ES2424393T3 (es)
HR (1) HRP20130728T1 (es)
IL (1) IL212070A (es)
MX (1) MX2011003500A (es)
MY (1) MY154337A (es)
NZ (1) NZ592008A (es)
PE (1) PE20110410A1 (es)
PL (1) PL2344471T3 (es)
PT (1) PT2344471E (es)
RS (1) RS52964B (es)
RU (1) RU2498981C2 (es)
SI (1) SI2344471T1 (es)
UA (1) UA105187C2 (es)
WO (1) WO2010038901A1 (es)
ZA (1) ZA201102315B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011219467A (ja) * 2010-03-26 2011-11-04 Taisho Pharmaceutical Co Ltd 7−ピペリジノアルキル−3,4−ジヒドロキノロン誘導体を含有する医薬
CA2816753A1 (en) 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
JP6062077B2 (ja) * 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物{phenylcarbamatecompoundsforuseinpreventingortreatingpediatricepilesyandepilesy−relatedsyndromes}
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションLycera Corporation レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
MX2018005004A (es) 2015-10-27 2018-09-12 Merck Sharp & Dohme Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
SI3413892T1 (sl) * 2016-02-12 2022-06-30 Cytokinetics, Incorporated Tetrahidroizokinolinski derivati

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4750663A1 (es) * 1995-09-15 1999-03-31 Sanofi Synthelabo Derivados de quinolein-2 (1h)-ona, su preparacion y su aplicacion en terapeutica
WO2003028641A2 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
SK2242004A3 (en) * 2001-10-25 2004-11-03 Takeda Chemical Industries Ltd Quinoline compound
US20050197350A1 (en) 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
WO2004087680A1 (en) 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Novel quinazoline derivatives and methods of treatment related to the use thereof
US20050209274A1 (en) * 2004-02-26 2005-09-22 Lynch John K Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
AU2005227997A1 (en) 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006035967A1 (en) 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
CA2666084A1 (en) 2006-10-06 2008-04-17 Taisho Pharmaceutical Co., Ltd. 1-naphthyl alkylpiperidine derivative

Also Published As

Publication number Publication date
CN102239159A (zh) 2011-11-09
CN102239159B (zh) 2014-06-25
DK2344471T3 (da) 2013-10-07
EP2344471A1 (en) 2011-07-20
IL212070A (en) 2014-07-31
EP2344471A4 (en) 2012-05-30
IL212070A0 (en) 2011-06-30
ZA201102315B (en) 2012-06-27
AU2009300607B2 (en) 2014-02-27
JP5541279B2 (ja) 2014-07-09
CA2739513A1 (en) 2010-04-08
PT2344471E (pt) 2013-08-01
CL2011000734A1 (es) 2011-09-23
RU2498981C2 (ru) 2013-11-20
RU2011117161A (ru) 2012-11-10
AU2009300607A1 (en) 2010-04-08
MX2011003500A (es) 2011-05-02
AU2009300607C1 (en) 2014-08-07
EP2344471B1 (en) 2013-07-24
SI2344471T1 (sl) 2013-11-29
RS52964B (sr) 2014-02-28
HK1159622A1 (en) 2012-08-03
AR073727A1 (es) 2010-11-24
UA105187C2 (uk) 2014-04-25
KR20110067026A (ko) 2011-06-20
JP2012504549A (ja) 2012-02-23
US20110178304A1 (en) 2011-07-21
WO2010038901A1 (en) 2010-04-08
BRPI0925343A2 (pt) 2015-07-28
CY1114165T1 (el) 2016-08-31
ES2424393T3 (es) 2013-10-01
HRP20130728T1 (en) 2013-10-11
NZ592008A (en) 2011-12-22
MY154337A (en) 2015-05-29
US8461182B2 (en) 2013-06-11
PL2344471T3 (pl) 2013-12-31
CO6321164A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
PE20110410A1 (es) Derivado de 7-piperidinoalquil-3,4-dihidroquinolona
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20080889A1 (es) Aminometil-4-imidazoles
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20110703A1 (es) Acidos naftilaceticos
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
PE20090893A1 (es) Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20081409A1 (es) Antagonistas del receptor de progesterona
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1
DK2081572T3 (da) Benzimidazol-cannabinoid-agonister med en substitueret heterocyklisk gruppe
PE20121614A1 (es) Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
PE20090521A1 (es) Malonamidas como antagonistas de orexina
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20090621A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
PE20110793A1 (es) Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona
PE20060878A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20070113A1 (es) Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb
PE20090592A1 (es) Nuevos derivados de piperazina-amida

Legal Events

Date Code Title Description
FC Refusal